This article is more than 5 years old. Information may no longer be current.
Decanted steroid, prophylactic IOP-lowering drugs treat macular edema in patients without glaucoma
Click Here to Manage Email Alerts
Decanted high-dose intravitreal triamcinolone acetonide, combined with prophylactic glaucoma medication, can be used to safely treat macular edema in non-glaucomatous eyes, according to a study.
The retrospective study included 65 eyes of 58 patients with macular edema secondary to retinal vein occlusion who received a total of 120 intravitreal injections of 20-mg decanted Kenalog (triamcinolone acetonide, Bristol-Myers Squibb). Twenty-nine patients received more than one injection, with a minimum of 3 months between injections.
IOP increased by 2 mm Hg at 4 months and reverted to baseline at 6 months in cases of consistent compliance with prophylactic IOP-lowering therapy (79.2%). IOP increased by 7 mm Hg at 1 month (P < .001) and returned to baseline after initiation of IOP-lowering treatment in cases of noncompliance with prophylactic therapy (20.8%).
The risk of experiencing an increase in IOP was 46% greater in non-vitrectomized eyes than in vitrectomized eyes.
Patients who complied poorly with IOP-lowering drugs had a 45% greater risk of experiencing an increase in IOP than compliant patients.
Non-vitrectomized eyes (P = .0098) and those with poor IOP-lowering drug compliance (P = .0019) had a significantly increased risk of IOP increasing to more than 21 mm Hg.
Disclosure: The authors have no relevant financial disclosures.
Click Here to Manage Email Alerts